Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

PCI 24781

  • Zoom
    PCI 24781
  • PCI 24781
Cat No: 20059
Biochemicals - Small Molecule Inhibitors
Cayman

PCI 24781 is an HDAC inhibitor that predominantly targets HDAC1 with a Ki value of 7 nM.{32732} It inhibits HDAC2, HDAC3/SMRT, HDAC6, HDAC8, and HDAC10 with Ki values of 19, 8.2, 17, 280, and 24 nM, respectively.{32732} PCI 24781 can prevent the growt...

More

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Synonyms:
  • 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide
Correlated keywords:
  • 883970-69-2 942630-54-8 PCI24781 CRA024781 CRA24781 hydroxamic HDAC caspase-8 deacetylase cytotoxicity FADD HDAC1 HDAC-2 3 6 8 10 anti-tumor DLD-1 HCT 116 abexinostat
Product Overview:
PCI 24781 is an HDAC inhibitor that predominantly targets HDAC1 with a Ki value of 7 nM.{32732} It inhibits HDAC2, HDAC3/SMRT, HDAC6, HDAC8, and HDAC10 with Ki values of 19, 8.2, 17, 280, and 24 nM, respectively.{32732} PCI 24781 can prevent the growth of tumor cells in vitro, inducing apoptosis, as well as in mice harboring HCT116 or DLD-1 colon tumor xenografts.{32732}
Size 1 mg
Shipping dry ice
CAS Number 783355-60-2
Molecular Formula C21H23N3O5
SMILES O=C(NO)C1=CC=C(OCCNC(C2=C(CN(C)C)C3=C(C=CC=C3)O2)=O)C=C1
Molecular Weight 397,4
Formulation A crystalline solid
Purity ≥95%
Custom Code 2922.19
UNSPSC code 12352100

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

/ We also advise you

Cross selling for this product : PCI 24781 There are 3 products.

Search